Viridian Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Good morning, everyone. Thank you for joining us at the Ladenburg Thalmann Virtual Healthcare Conference. My name is Michael Higgins, Managing Director, Senior Biotech Analyst here at the firm. I'm pleased to introduce today a Company I cover, Viridian Therapeutics. A friend of mine, [Jon] Violin, is Co-Founder and CEO. Jon, I'll let you take it away. We will have a little time at the end then for Q&A. Correct?
Great. Yes, thanks, Michael, and thanks, everyone, for joining. So given that we are a relatively new Company still, I thought I would go through our corporate deck, but I do want to save some time for Q&A. So we will probably give a light touch to a few of our slides here. So thanks again for spending your time with us.
And of course before we get started, please see our SEC filings for our risk statements. I will be making forward-looking statements. And as an overview of Viridian, so we formed the Company last year and are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |